Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Samer Khosrof

Ophthalmology Brooklyn, NY Medical Doctor

NPI 1629138540 CMS profile 255641

333 86Th St, Suite 1B, Brooklyn, NY 11209

Open in the dashboard

General payments

$538

10 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Samer Khosrof of Brooklyn, NY is reported in the CMS Open Payments database as having received $538 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2023 General $15 1
2022 General $185 1
2021 General $78 1
2020 General $79 3
2019 General $165 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samer Khosrof
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Samer Khosrof were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Samer Khosrof Ophthalmology median Middle half National median
2019 $165 $258 $104–$655 $163
2020 $79 $126 $45–$321 $114
2021 $78 $205 $76–$534 $132
2022 $185 $266 $100–$678 $149
2023 $15 $308 $117–$745 $160
2024 $16 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Carl Zeiss Meditec USA, Inc. $262 2 payments
  2. Alcon Vision LLC $171 5 payments
  3. Carl Zeiss Meditec, Inc. $85 2 payments
  4. Carl Zeiss Meditec AG $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $458 7 payments
  2. Education $60 2 payments
  3. Gift $19 1 payment
Products named General payments · program years 2019–2024
  1. LUMERA 700 $185 1 payment
  2. VisuMax Surgical Optical Laser $85 2 payments
  3. VisuMax Surgical Optical Laser $78 1 payment
  4. Wavelight $60 2 payments
  5. None Specified $19 1 payment
  6. Clareon $16 1 payment
  7. Wavelight Refractive Suite $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,431

Median for Ophthalmology: 891

Drug cost

$135,296

Median for Ophthalmology: $68,233

Branded share of claims

34.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 134 $43,628
Tobradex Tobramycin/Dexamethasone Brand 54 $14,268
Loteprednol Etabonate Generic 73 $10,060
Alphagan P Brimonidine Tartrate Brand 35 $9,971
Combigan Brimonidine Tartrate/Timolol Brand 32 $9,075
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 35 $7,006
Zirgan Ganciclovir Brand 14 $6,358
Lotemax Loteprednol Etabonate Brand 19 $6,132
Prolensa Bromfenac Sodium Brand 15 $5,112
Brinzolamide Generic 36 $4,669

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$192,745

Of which drugs: $31,638

Medicare patients

150

Average age 74

Services billed

1,904

81 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 63%
Arthritis 55%
Ischemic heart disease 37%
Chronic kidney disease 21%
COPD 21%
Heart failure 20%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bevacizumab, 10 mg J9035 Office 16 185 $10,608

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record